类固醇-他克莫司药物相互作用及CYP3A基因型的影响
基于2462例肾移植受者,按CYP3A5*3/*6/*7和CYP3A4*22功能丢失等位基因数分层,分析移植后6个月内类固醇使用对他克莫司清除率的影响。群体药代动力学分析显示类固醇使他克莫司清除率轻度升高3%-11.8%,且升高幅度随功能丢失等位基因数不同而异。
要点
- 类固醇使他克莫司清除率升高3%-11.8%,幅度因CYP3A基因型而异。
- 0个功能丢失等位基因者合用类固醇时清除率升高最明显(11.8%)。
- 2个功能丢失等位基因者合用类固醇时清除率升高仅2.6%,几乎可忽略。
核心结论
- 类固醇增加他克莫司清除率,但升高幅度随CYP3A基因型略有差异。
- 该差异对更可能携带0个功能丢失等位基因、更常接受类固醇治疗且需要更高他克莫司剂量的非洲裔个体具有重要意义。
研究设计与样本
- 纳入2462例肾移植受者,按CYP3A5*3、*6、*7和CYP3A4*22功能丢失等位基因数分类,并记录移植后6个月内每个他克莫司谷浓度时的类固醇使用情况。
- 采用非线性混合效应模型(NONMEM)进行群体药代动力学分析,并通过逐步协变量建模确定影响他克莫司清除率的显著协变量。
- 进行了随机模拟,并使用R语言的mrgsolve和Shiny包转化为Shiny应用。
主要发现
- 类固醇与他克莫司清除率轻度升高3%-11.8%相关。
- 0个功能丢失等位基因者合用类固醇时清除率升高最明显(11.8%),而2个功能丢失等位基因者仅升高2.6%。
- 1个功能丢失等位基因者和3/4个功能丢失等位基因者合用类固醇时清除率分别升高5%和10.3%。
临床怎么用
- 肾移植后合用类固醇时,应关注CYP3A基因型对他克莫司清除率影响的差异,尤其对0个功能丢失等位基因者可能需要更高他克莫司剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Tacrolimus, metabolized by CYP3A4 and CYP3A5 enzymes, is susceptible to drug-drug interactions (DDI). Steroids induce CYP3A genes to increase tacrolimus clearance, but the effect is variable. We hypothesized that the extent of the steroid-tacrolimus DDI differs by CYP3A4/5 genotypes. METHODS: Kidney transplant recipients (n = 2462) were classified by the number of loss of function alleles (LOF) (CYP3A5*3, *6 and *7 and CYP3A4*22) and steroid use at each tacrolimus trough in the first 6 months post-transplant. A population pharmacokinetic analysis was performed by nonlinear mixed-effect modelling (NONMEM) and stepwise covariate modelling to define significant covariates affecting tacrolimus clearance. A stochastic simulation was performed and translated into a Shiny application with the mrgsolve and Shiny packages in R. RESULTS: Steroids were associated with modestly higher (3%-11.8%) tacrolimus clearance. Patients with 0-LOF alleles receiving steroids showed the greatest increase (11.8%) in clearance compared to no steroids, whereas those with 2-LOFs had a negligible increase (2.6%) in the presence of steroids. Steroid use increased tacrolimus clearance by 5% and 10.3% in patients with 1-LOF and 3/4-LOFs, respectively. CONCLUSIONS: Steroids increase the clearance of tacrolimus but vary slightly by CYP3A genotype. This is important in individuals of African ancestry who are more likely to carry no LOF alleles, may more commonly receive steroid treatment, and will need higher tacrolimus doses.
引用
- Saqr A, Al-Kofahi M, Mohamed M, et al. Steroid-tacrolimus drug-drug interaction and the effect of CYP3A genotypes. Br J Clin Pharmacol. 2024. PMID: 38994750. doi:10.1111/bcp.16172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。